Home
Bjørn Tore Gjertsen's picture

Bjørn Tore Gjertsen

Professor
  • E-mailBjorn.Gjertsen@uib.no
  • Phone+47 55 97 29 68+47 415 66 248
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Selected publications
  • Reikvam, Håkon; Hovland, Randi; Forthun, Rakel Brendsdal; Erdal, Sigrid; Gjertsen, Bjørn Tore; Fredly, Hanne Kristin; Bruserud, Øystein. 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 17:630: 1-13. doi: 10.1186/s12885-017-3620-y
  • Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela Lucia; Liu, Minxia; Javarappa, Komal K.; Majumder, Muntasir Mamun; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Mayoral Safont, Mireia; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjørn Tore; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline Akemi. 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 130: 789-802. doi: 10.1182/blood-2016-02-699363
  • Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Thobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Mohammed Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore. 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 102: 1361-1367. doi: 10.3324/haematol.2017.167080
  • Rajala, Hanna L.M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Janssen, Jeroen; Lotfi, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu. 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 143: 1543-1554. doi: 10.1007/s00432-017-2378-6
  • Omsland, Maria; Bruserud, Øystein; Gjertsen, Bjørn Tore; Andresen, Vibeke. 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 8: 7946-7963. doi: 10.18632/oncotarget.13853
  • Sopper, Sieghart; Mustjoki, Satu; White, Deborah; Hughes, Timothy; Valent, Peter; Burchert, Andreas; Gjertsen, Bjørn Tore; Gastl, Günther; Baldauf, Matthias; Trajanoski, Zlatko; Giles, Frank; Hochhaus, Andreas; Ernst, Thomas; Schenk, Thomas; Janssen, Jeroen J.W.M.; Ossenkoppele, Gert J.; Porkka, Kimmo; Wolf, Dominik. 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 35: 175-184. doi: 10.1200/JCO.2016.67.0893
  • Kotopoulis, Spiros; Stigen, Endre; Popa, Mihaela Lucia; Mayoral Safont, Mireia; Healey, Andrew; Kvåle, Svein; Sontum, Per; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet. 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 245: 70-80. doi: 10.1016/j.jconrel.2016.11.019
  • Kontro, Mika; Kumar, Anil; Majumder, Muntasir Mamun; Eldfors, Samuli; Parsons, Alun; Pemovska, Tea; Saarela, Janna; Yadav, Bhagwan; Malani, Disha; Fløisand, Yngvar; Höglund, Martin; Remes, Kari Juhani; Gjertsen, Bjørn Tore; Kallioniemi, Olli; Wennerberg, Krister; Heckman, Caroline Akemi; Porkka, Kimmo. 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 31: 301-309. doi: 10.1038/leu.2016.222
  • Andresen, Vibeke; Erikstein, Bjarte Skoe; Mukherjee, Herschel; Sulen, Andre; Popa, Mihaela Lucia; Sørnes, Steinar; Reikvam, Håkon; Chan, Kok-Ping; Hovland, Randi; McCormack, Emmet; Bruserud, Øystein; Myers, Andrew G.; Gjertsen, Bjørn Tore. 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 7:e2497: 1-14. doi: 10.1038/cddis.2016.392
  • Thielen, Noortje; Richter, Johan; Baldauf, Matthias; Barbany, Gisela; Fioretos, Thoas; Giles, Francis; Gjertsen, Bjørn Tore; Hochhaus, Andreas; Schuurhuis, Gerrit Jan; Sopper, Sieghart; Stenke, Leif; Thunberg, Sarah; Wolf, Dominik; Ossenkoppele, Gert; Porkka, Kimmo; Janssen, Jeroen; Mustjoki, Satu. 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 22: 4030-4038. doi: 10.1158/1078-0432.CCR-15-2791
  • Sulen, Andre; Gjertsen, Bjørn Tore. 2016. Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability. Universitetet i Bergen.
  • Helland, Øystein; Popa, Mihaela Lucia; Bischof, Katharina; Gjertsen, Bjørn Tore; McCormack, Emmet; Bjørge, Line. 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE. 11:e0158208. doi: 10.1371/journal.pone.0158208
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 243: 172-181. doi: 10.1016/j.jconrel.2016.10.007
  • Sulen, Andre; Gullaksen, Stein-Erik; Bader, Lucius; McClymont, David; Skavland, Jørn; Gavasso, Sonia; Gjertsen, Bjørn Tore. 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 113: 216-227. doi: 10.1016/j.phrs.2016.08.018
  • Hjorth-Hansen, Henrik; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Höglund, Martin; Dreimane, Arta; Porkka, Kimmo; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Gruber, Franz; Stenke, Leif; Myhr-Eriksson, Kristina; Markevärn, Berit; Lübking, Anna; Vestergaard, Hanne; Udby, Lene; Bjerrum, Ole Weis; Persson, Inger; Mustjoki, Satu; Olsson-Strömberg, Ulla. 2016. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30: 1853-1860. doi: 10.1038/leu.2016.121
  • Sulen, Andre; Lygre, Stein Håkon Låstad; Hjelle, Sigrun Margrethe; Hollund, Bjørg Eli; Gjertsen, Bjørn Tore. 2016. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Scientific Reports. 6:29060. doi: 10.1038/srep29060
  • Leitch, Calum; Osdal, Tereza; Andresen, Vibeke; Molland, Maren Kristine Butler; Kristiansen, Silje Elisabeth; Nguyen, Nhi Xuan; Bruserud, Øystein; Gjertsen, Bjørn Tore; McCormack, Emmet. 2016. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 7: 8105-8118. doi: 10.18632/oncotarget.6991
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology. 34:e15703.
  • Gavasso, Sonia; Gullaksen, Stein-Erik; Skavland, Jørn; Gjertsen, Bjørn Tore. 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 16: 579-589. doi: 10.1586/14737159.2016.1156531
  • Kotopoulis, Spiros; Dimcevski, Georg Gjorgji; McCormack, Emmet; Postema, Michiel; Gjertsen, Bjørn Tore; Gilja, Odd Helge. 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. Journal of the Acoustical Society of America. 139: 2092-2092. doi: 10.1121/1.4950209
  • Engen, Caroline Benedicte Nitter; Hajjar, Ehsan; Gjertsen, Bjørn Tore. 2016. Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 17: 20-29. doi: 10.2174/1389201016666150930115024
Academic article
  • Show author(s) 2020. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine. 1-13.
  • Show author(s) 2019. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports. 1-15.
  • Show author(s) 2019. Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. Cancers. 1-25.
  • Show author(s) 2019. Intracellular signaling in key pathways is induced by treatment with ultrasound and microbubbles in a leukemia cell line, but not in healthy peripheral blood mononuclear cells. Pharmaceutics. 1-17.
  • Show author(s) 2018. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Show author(s) 2018. Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. Biomarker Research.
  • Show author(s) 2018. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 1768-1777.
  • Show author(s) 2018. Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian Mother and Child Cohort Study. British Journal of Cancer. 1028-1035.
  • Show author(s) 2018. Inhibition of tunneling nanotube (TNT) formation and Human T-cell leukemia virus type 1 (HTLV-1) transmission by cytarabine. Scientific Reports. 1-17.
  • Show author(s) 2018. High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • Show author(s) 2018. Gene expression response in peripheral blood cells of petroleum workers exposed to sub-ppm benzene levels. International Journal of Environmental Research and Public Health (IJERPH). 1-18.
  • Show author(s) 2018. Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. . Stem Cell Research & Therapy. 1-15.
  • Show author(s) 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 1543-1554.
  • Show author(s) 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 7946-7963.
  • Show author(s) 2017. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 1636-1645.
  • Show author(s) 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 70-80.
  • Show author(s) 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 1361-1367.
  • Show author(s) 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 175-184.
  • Show author(s) 2017. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
  • Show author(s) 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 789-802.
  • Show author(s) 2017. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer Journal. 4 pages.
  • Show author(s) 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 301-309.
  • Show author(s) 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 1-13.
  • Show author(s) 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE.
  • Show author(s) 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 216-227.
  • Show author(s) 2016. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 1853-1860.
  • Show author(s) 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 4030-4038.
  • Show author(s) 2016. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 8105-8118.
  • Show author(s) 2016. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Scientific Reports.
  • Show author(s) 2016. Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 20-29.
  • Show author(s) 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 1-14.
  • Show author(s) 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 172-181.
  • Show author(s) 2015. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its aml-associated mutants. ACS Chemical Biology. 855-863.
  • Show author(s) 2015. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006). European Journal of Haematology. 243-250.
  • Show author(s) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Show author(s) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Show author(s) 2014. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukemic compound PEP005 in primary AML cells. Oncoscience. 529-539.
  • Show author(s) 2014. Sonoporation: from the lab to human clinical trials. IEEE International Ultrasonics Symposium Proceedings. 846-849.
  • Show author(s) 2014. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Molecular Imaging and Biology. 53-62.
  • Show author(s) 2014. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 431-446.
  • Show author(s) 2014. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer.
  • Show author(s) 2014. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLOS ONE.
  • Show author(s) 2014. Evaluation of the effects of clinical diagnostic ultrasound in combination with ultrasound contrast agents on cell stress: Single cell analysis of intracellular phospho-signaling pathways in blood cancer cells and normal blood leukocytes. IEEE International Ultrasonics Symposium Proceedings. 1186-1190.
  • Show author(s) 2014. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leukemia and Lymphoma. 2114-2119.
  • Show author(s) 2013. cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. International Journal of Oncology. 1815-1821.
  • Show author(s) 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics.
  • Show author(s) 2013. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 30-47.
  • Show author(s) 2013. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Research. 1276-1286.
  • Show author(s) 2013. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. E34-E42.
  • Show author(s) 2013. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery. 1416-1429.
  • Show author(s) 2013. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs. 551-563.
  • Show author(s) 2013. Gel2DE-A software tool for correlation analysis of 2D gel electrophoresis data. BMC Bioinformatics. 5 pages.
  • Show author(s) 2013. Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer.
  • Show author(s) 2013. Expression of TP53 isoforms p53 beta or p53 gamma enhances chemosensitivity in TP53(null) cell lines. PLOS ONE. 11 pages.
  • Show author(s) 2013. Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicology. 13 pages.
  • Show author(s) 2013. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death & Disease.
  • Show author(s) 2013. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. Cancer Immunology and Immunotherapy. 773-785.
  • Show author(s) 2012. Volume visualization for exploration of population trends in two-dimensional gel electrophoresis protein data. Computer-Based Medical Systems. 1-6.
  • Show author(s) 2012. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 910-917.
  • Show author(s) 2012. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. Journal of Proteomics. 69-78.
  • Show author(s) 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 1116-1124.
  • Show author(s) 2012. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 468-480.
  • Show author(s) 2012. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology. 201-212.
  • Show author(s) 2012. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLOS ONE.
  • Show author(s) 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 1533-1545.
  • Show author(s) 2011. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal.
  • Show author(s) 2010. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leukemia Research. 77-84.
  • Show author(s) 2010. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutrition and Cancer. 574-583.
  • Show author(s) 2010. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology.
  • Show author(s) 2010. Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. European Cytokine Network. 154-164.
  • Show author(s) 2010. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. Hematology. 338-343.
  • Show author(s) 2010. Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment. Journal of Cellular Biochemistry. 574-584.
  • Show author(s) 2010. Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. Journal of Immunology. 4547-4556.
  • Show author(s) 2009. Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 1-41.
  • Show author(s) 2009. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumour model. Neoplasia. 812-822.
  • Show author(s) 2009. Er høyt hemoglobinnivå farlig? Tidsskrift for Den norske legeforening. 1881-1882.
  • Show author(s) 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 287-293.
  • Show author(s) 2008. Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. European Journal of Oral Sciences. 23-30.
  • Show author(s) 2008. In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs. 1623-1633.
  • Show author(s) 2008. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2866-2877.
  • Show author(s) 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 814-828.
  • Show author(s) 2007. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology and Immunotherapy. 013-925.
  • Show author(s) 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 332-341.
  • Show author(s) 2007. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer.
  • Show author(s) 2007. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Molecular Cancer.
  • Show author(s) 2007. In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. Molecular Imaging. 193-204.
  • Show author(s) 2007. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Current Pharmaceutical Biotechnology. 388-400.
  • Show author(s) 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 1529-1538.
  • Show author(s) 2007. Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 2589-2596.
  • Show author(s) 2007. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 13-24.
  • Show author(s) 2007. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 210-225.
  • Show author(s) 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • Show author(s) 2007. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 199-207.
  • Show author(s) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 1065-1080.
  • Show author(s) 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research. 1531-1540.
  • Show author(s) 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 159-170.
  • Show author(s) 2006. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia? Cancer Immunology and Immunotherapy. 221-228.
  • Show author(s) 2006. Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics. 198.
  • Show author(s) 2006. CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation. 1191-1202.
  • Show author(s) 2006. Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment. Electrophoresis. 4086-4095.
  • Show author(s) 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 3985-3992.
  • Show author(s) 2005. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 631-646.
  • Show author(s) 2005. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leukemia Research. 185-196.
  • Show author(s) 2005. CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry. 18-27.
  • Show author(s) 2004. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 217-228.
  • Show author(s) 2004. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2925-2928.
  • Show author(s) 2004. Rituximab for pimary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2925-2928.
  • Show author(s) 2004. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica. 391-402.
  • Show author(s) 2004. Khat (Catha edulis)-induced apoptosis is inhibited by antagonists of caspase-1 and -8 in human leukaemia cells. British Journal of Cancer. 1726-1726.
  • Show author(s) 2004. How should clinical data be included in experimental studies of cancer immunology? Cancer Immunology and Immunotherapy. 677-680.
  • Show author(s) 2004. Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease. Scandinavian Journal of Immunology. 189-198.
  • Show author(s) 2004. Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia. 1989-1996.
  • Show author(s) 2000. Patterns of cell death induced by eluates from denture base acrylic resins in U-937 human monoblastoid cells. European Journal of Oral Sciences. 59-69.
  • Show author(s) 2000. In vitro Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines. Journal of Hematotherapy & Stem Cell Research. 923-932.
  • Show author(s) 1999. Ultrarapid apoptosis inducted by phosphatase inhibitors. Cell Death Differ. Cell Death and Differentiation. 1099-1108.
  • Show author(s) 1999. Caspase I related protease inhibition retards the execution of okadaic acid and camptothecin induced apoptosis and PAI-2 selective cleavage, but not commitment to cell death in HL-60 cells. British Journal of Cancer. 1685-1691.
  • Show author(s) 1998. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology. 19-24.
  • Show author(s) 1997. Gap junctions and growth control in liver regeneration and in isolated rat hepatocytes. Hepatology. 847-855.
  • Show author(s) 1997. Fas/APO-1 (CD95)-Induced Apoptosis of Primary Hepatocytes Is Inhibited by cAMP. Biochemical and Biophysical Research Communications - BBRC. 20-25.
  • Show author(s) 1996. Kreftcellens skjulte veier til apotose. Kreftnytt.
  • Show author(s) 1994. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. Journal of Cell Science, Supplement. 3363-3377.
  • Show author(s) 1994. Cleaved intracellular plasminogen activator inhibitor-2 is a marker of apoptosis present in human myeloid leukemia cells. British Journal of Cancer. 834-840.
  • Show author(s) 1993. The genetic subtypes of cAMP-dependent protein kinase - functionally different or redundant? Biochimica et Biophysica Acta. 249-258.
  • Show author(s) 1993. Microinjected catalytic subunit of cAMP-dependent protein kinase induces apoptosis in myeloid leukemic (IPC-81) cells. Exp Cell Res. 157-161.
  • Show author(s) 1993. Exogenous substrate stimulate autodephosphorylation of cyclic-AMP-dependent protein kinase II. Biochemical Journal. 497-503.
  • Show author(s) 1993. Apoptotisk celledød. NBS-nytt. 6-12.
  • Show author(s) 1993. Apoptosisk celledød - finnes det fornuft i fragmenteringen? NBS-nytt. 6-12.
  • Show author(s) 1993. Anti-apoptotic effect of heterozygously expressed mutant RI (Ala%3%3%6 ->Asp) subunit of cAMP-kinase I in a rat leukaemia cell line. Journal of Biological Chemistry. 8332-8340.
  • Show author(s) 1991. The protein phosphatase inhibator okadaic acid induces morphological changes typical of apoptosis in mammalian cells. Experimental Cell Research. 237-246.
  • Show author(s) 1991. Programmed cell death (apoptosis) is induced rapidly and with positive cooperativity by activation of cyclic adenosine monophosphate-kinase I in a myeloid leukemia cell line. Journal of Cellular Physiology. 73-80.
Academic lecture
  • Show author(s) 2017. Proteomics and single cell immune and signaling profiling of myeloid leukemia.
  • Show author(s) 2015. Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume.
  • Show author(s) 2013. Phosphoprotein signaling in acute myeloid leukemia.
  • Show author(s) 2007. Early protein and gene modulation in response to induction chemotherapy of acute myeloid leukemia.
  • Show author(s) 2007. Early Protein and Gene Modulation in Response to Induction Chemotherapy of Acute Myeloid Leukemia.
  • Show author(s) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Show author(s) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Show author(s) 2005. Molecular mechanisms of apoptosis induced by khat extract and its alkaloids cathinone and cathine in acute myeloid leukemia.
  • Show author(s) 2005. Mechanisms of apoptosis induction by khat alkaloids in leukaemia cells.
  • Show author(s) 2005. Khat- and cathionine-induced apoptosis is modulated by Bcl-2 protein expression.
  • Show author(s) 2005. Individualizing therapy in acute myeloid leukemia through modulation of signaling networks.
  • Show author(s) 2005. Discovering candidate genes that distinguish between CML and AML using microarrays.
  • Show author(s) 1998. Ultrarapid apoptosis induction in a variety of cell types injected with phosphatase inhibitors is mediated through Ca2 /calmodulin dependent protei kinase activity.
  • Show author(s) 1994. Multiple apoptotic death types induced via separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line.
  • Show author(s) 1993. Signal-induced Apoptosis in Myeloid Leukemia. Apoptosis or Programmed Cell Death. From Basic Research to Clinical Application.
  • Show author(s) 1993. "Cyclic AMP dependent protein kinase and phosphatase inhibitors induces different phenotypic forms of cell death.".
Abstract
  • Show author(s) 2018. Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. Annals of Oncology. viii452-viii452.
  • Show author(s) 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
  • Show author(s) 2013. PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. International Journal of Gynecological Cancer. 1 pages.
  • Show author(s) 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 18-19.
  • Show author(s) 2012. Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. Acta Obstetricia et Gynecologica Scandinavica. 16-17.
  • Show author(s) 2012. A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. Blood. 2 pages.
  • Show author(s) 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • Show author(s) 2010. OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. Experimental Hematology. S119-S119.
  • Show author(s) 2010. Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 510-510.
  • Show author(s) 2009. TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. Neuro-Oncology. 965-965.
  • Show author(s) 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
  • Show author(s) 2008. FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. Haematologica. 10-10.
  • Show author(s) 2008. Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. Blood. 1024-1024.
  • Show author(s) 2007. Synergistic anti-leukemic effect of protein kinase a activator and PPAR7agonist is independent of Bcl-2 status. Blood. 117B-117B.
  • Show author(s) 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 77-77.
  • Show author(s) 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 112-112.
  • Show author(s) 2007. Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. Blood. 148B-148B.
  • Show author(s) 2007. Discrimination and quantification of spectrally similar near-infrared probes by time-domain (TD) optical imaging in acute myeloid leukemia mouse models. Blood. 147B-148B.
  • Show author(s) 2007. Anti-tumor activity of immunoproteasome selective inhibitors. Blood. 477A-478A.
  • Show author(s) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 106.
  • Show author(s) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. S65.
  • Show author(s) 2005. The role of Bcl-2 in apoptosis induced by khat (Catha edulis) in acute myeloid leukemia cell lines. Blood. 195b-195b.
  • Show author(s) 2001. Vitamin E prevents apoptosis and necrosis in U-937 cells exposed to eluates from autopolymerized denture base acrylic resins. Journal of Dental Research. 1291-1291.
  • Show author(s) 1999. Altered clonogenicity and induction of apoptotic cell death in L929 cells exposed to denture base acrylic resins. Journal of Dental Research. 315-315.
  • Show author(s) 1998. A comparative study of cytopathogenic effects of four denture base acrylic resins. Journal of Dental Research. 816-816.
Academic literature review
  • Show author(s) 2021. Colony stimulating factor 1 receptor in acute myeloid leukemia. Frontiers in Oncology. 1-12.
  • Show author(s) 2019. Clinical trials of repurposing medicines in acute myeloid leukemia: Limitations and possibilities in the age of precision therapy. The Cancer Journal. 153-163.
  • Show author(s) 2017. Drug Repurposing for the Treatment of Acute Myeloid Leukemia. Frontiers in medicine.
  • Show author(s) 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 579-589.
  • Show author(s) 2015. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 11-19.
  • Show author(s) 2013. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics.
  • Show author(s) 2012. Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? Expert Opinion on Investigational Drugs. 587-603.
  • Show author(s) 2012. Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid. Espert Review of Proteomics. 595-598.
  • Show author(s) 2012. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European Journal of Clinical Investigation. 1016-1026.
  • Show author(s) 2011. Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. Journal of Proteomics. 269-281.
  • Show author(s) 2011. Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling. Expert Review of Anticancer Therapy. 355-357.
  • Show author(s) 2010. Clinical proteomics of myeloid leukemia. Genome Medicine.
  • Show author(s) 2009. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs. 433-455.
  • Show author(s) 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 6-22.
  • Show author(s) 2008. Review: genetic models of acute myeloid leukaemia. Oncogene. 3765-3779.
  • Show author(s) 2008. Effects of benzene on human hematopoiesis. The Open Hematology Journal. 87-102.
  • Show author(s) 2008. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets. 666-675.
  • Show author(s) 2007. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert opinion on therapeutic targets. 1055-1069.
  • Show author(s) 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 344-354.
  • Show author(s) 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy. 741-751.
  • Show author(s) 2007. Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. Current Pharmaceutical Biotechnology. 373-381.
  • Show author(s) 2006. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Current Pharmaceutical Biotechnology. 199-207.
  • Show author(s) 2006. Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. Current Pharmaceutical Biotechnology. 185-198.
  • Show author(s) 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 159-170.
  • Show author(s) 2006. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert opinion on therapeutic targets. 51-68.
  • Show author(s) 2006. Immunotherapy in chronic lymphocytic leukemia. Cancer Immunology and Immunotherapy. 185-187.
  • Show author(s) 2005. Proteomics in acute myelogenous leukaemia (AML): Methodological strategies-and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 631-646.
  • Show author(s) 2005. Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets. 229-248.
  • Show author(s) 2005. Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia. 687-706.

More information in national current research information system (CRIStin)